ACA reform must preserve mental health pharmacy accessACA repeal or replacement must focus on how to preserve mental health services and pharmacy access.
Four areas of unnecessary senior healthcare
Four areas of unnecessary senior healthcareTwo reports highlight areas of elderly care that healthcare systems and health plans should avoid.
Risk of neutropenia prompts new monitoring for antipsychotic drugFDA announced new requirements for the monitoring, prescribing, and dispensing of clozapine, an atypical antipsychotic for treatment-resistant schizophrenia, due to the continued risk of severe neutropenia, which can be life-threatening.
First-in-class therapy promising for Parkinson's disease psychosisA first-in-class antipsychotic that is a selective serotonin inverse agonist (with no dopaminergic, histaminergic, adrenergic, or muscarinic activity) potentially targeting 5-HT2A receptors, improved Parkinson’s disease psychosis (PDP) with demonstrated safety and tolerability, and without worsening motor Parkinson’s, according to data presented in two posters at the 19th International Congress of Parkinson’s Disease and Movement Disorders (MDS), in San Diego.
Long-acting schizophrenia drug may help with medication adherenceFDA has approved the first and only 4-times-per-year schizophrenia drug.
FDA moves forward with approval of generic Abilify from 4 different manufacturers despite Otsuka pushbackFDA’s approval of generic versions of Abilify (aripiprazole), an antipsychotic drug approved to treat schizophrenia and bipolar disorder, from 4 different generic manufacturers, has industry insiders pondering the generic drug market.
FDA approves first generic AbilifyThe FDA approved the first generic versions of Abilify (aripiprazole), an antipsychotic drug approved to treat schizophrenia and bipolar disorder, on April 28.
Children’s use of antipsychotics may increase risk of diabetesInitiating antipsychotics may elevate a child’s risk not only for significant weight gain, but also for type 2 diabetes by nearly 50%, according to a study in JAMA Pediatrics. Moreover, among children who are also receiving antidepressants, the risk may double.
Letter details pediatric antipsychotic medication problemsRestrictive Medicaid prior authorization policies are leading to substitution of potentially inappropriate, off-label psychotropic medication use and other problems in prescribing antipsychotic medications for children, according to a recent research letter.
First atypical antipsychotic approved for pediatric patients with bipolar I disorder in 5 yearsFDA has approved asenapine (Saphris, Actavis) for treatment of manic or mixed episodes of bipolar I disorder in pediatric patients, ages 10 to 17 years old.